ATE412650T1 - Isethionat salz eines selektiven cdk4 inhibitors - Google Patents

Isethionat salz eines selektiven cdk4 inhibitors

Info

Publication number
ATE412650T1
ATE412650T1 AT04737186T AT04737186T ATE412650T1 AT E412650 T1 ATE412650 T1 AT E412650T1 AT 04737186 T AT04737186 T AT 04737186T AT 04737186 T AT04737186 T AT 04737186T AT E412650 T1 ATE412650 T1 AT E412650T1
Authority
AT
Austria
Prior art keywords
cdk4 inhibitor
selective cdk4
isethionate salt
isethionate
salt
Prior art date
Application number
AT04737186T
Other languages
English (en)
Inventor
Vladimir Genukh Beylin
Anthony Clyde Blackburn
David Erdman
Peter Laurence Toogood
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE412650T1 publication Critical patent/ATE412650T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AT04737186T 2003-07-11 2004-06-28 Isethionat salz eines selektiven cdk4 inhibitors ATE412650T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48635103P 2003-07-11 2003-07-11

Publications (1)

Publication Number Publication Date
ATE412650T1 true ATE412650T1 (de) 2008-11-15

Family

ID=34062121

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04737186T ATE412650T1 (de) 2003-07-11 2004-06-28 Isethionat salz eines selektiven cdk4 inhibitors

Country Status (32)

Country Link
US (2) US7345171B2 (de)
EP (1) EP1648889B1 (de)
JP (1) JP4053073B2 (de)
KR (1) KR100816945B1 (de)
CN (1) CN1835951B (de)
AR (1) AR045898A1 (de)
AT (1) ATE412650T1 (de)
AU (1) AU2004255934B2 (de)
BR (1) BRPI0412516A (de)
CA (1) CA2532049C (de)
CL (1) CL2004001701A1 (de)
CY (1) CY1108589T1 (de)
DE (1) DE602004017474D1 (de)
DK (1) DK1648889T3 (de)
ES (1) ES2313016T3 (de)
GT (1) GT200400130A (de)
HK (1) HK1091205A1 (de)
IL (1) IL173034A (de)
MX (1) MXPA06000484A (de)
NL (1) NL1026624C2 (de)
NO (1) NO335100B1 (de)
NZ (1) NZ544609A (de)
PA (1) PA8606501A1 (de)
PE (1) PE20050700A1 (de)
PL (1) PL1648889T3 (de)
PT (1) PT1648889E (de)
RU (1) RU2317296C2 (de)
SI (1) SI1648889T1 (de)
TW (1) TWI288750B (de)
UY (1) UY28404A1 (de)
WO (1) WO2005005426A1 (de)
ZA (1) ZA200600230B (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE314370T1 (de) 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
JP2007530654A (ja) * 2004-03-30 2007-11-01 ファイザー・プロダクツ・インク シグナル伝達阻害剤の組合せ
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
CA2624965A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Pyridopyrimidinone inhibitors of pi3k.alpha.
BRPI0716880A2 (pt) * 2006-09-08 2013-10-15 Pfizer Prod Inc Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
WO2008032162A1 (en) 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
AU2007333791A1 (en) * 2006-12-14 2008-06-26 Panacea Pharmaceuticals, Inc. Methods of neuroprotection by cyclin-dependent kinase inhibition
WO2009061345A2 (en) * 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
MX2010010975A (es) * 2008-04-07 2010-11-01 Amgen Inc Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
AU2009298367A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
AU2009310352A1 (en) * 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
CN102458443A (zh) 2009-05-13 2012-05-16 北卡罗来纳大学查珀尔希尔分校 细胞周期蛋白依赖性激酶抑制剂及使用方法
BR112012012156A2 (pt) 2009-11-06 2015-09-08 Plexxikon Inc compostos e métodos para modulação de cinase, e indicações para esta
SG182297A1 (en) 2009-12-31 2012-08-30 Ct Nac Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
JP2013545758A (ja) * 2010-11-17 2013-12-26 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 増殖性キナーゼｃｄｋ４及びｃｄｋ６の阻害による虚血からの腎組織の保護
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
TR201816421T4 (tr) 2011-02-07 2018-11-21 Plexxikon Inc Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları.
KR20160035613A (ko) 2011-03-23 2016-03-31 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
EP2721686B1 (de) 2011-06-17 2018-11-28 NantEnergy, Inc. Ionische flüssigkeit mit sulfonationen
EP3216792B1 (de) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactamkinaseinhibitoren
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
KR101858913B1 (ko) * 2013-02-21 2018-05-16 화이자 인코포레이티드 고체 형태의 선택적인 cdk4/6 억제제
WO2014144740A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
US9527857B2 (en) 2013-03-15 2016-12-27 GI Therapeutics, Inc. HSPC-sparing treatments for RB-positive abnormal cellular proliferation
CA2904054A1 (en) * 2013-03-15 2014-09-25 Concert Pharmaceuticals, Inc. Deuterated palbociclib
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
US20150297606A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
JP6631616B2 (ja) * 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
US20170217962A1 (en) * 2014-07-31 2017-08-03 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
WO2016024249A1 (en) * 2014-08-14 2016-02-18 Sun Pharmaceutical Industries Limited Crystalline forms of palbociclib
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
EP4183806A3 (de) 2014-11-12 2023-08-02 Seagen Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
RS59782B1 (sr) * 2015-02-03 2020-02-28 Jiangsu hengrui medicine co ltd Hidroksietil sulfonat od ciklina zavisnog inhibitora kinaze proteina, njegov kristalni oblik, i postupak za njegovo dobijanje
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
EP3078663A1 (de) 2015-04-09 2016-10-12 Sandoz Ag Modifizierte partikel von palbociclib
CN104910149A (zh) * 2015-04-28 2015-09-16 上海百奇医药科技有限公司 一种Palbociclib制备方法
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
PL3305785T3 (pl) * 2015-05-29 2021-12-27 Teijin Pharma Limited Pochodna pirydo[3,4-d]pirymidyny i jej farmaceutycznie dopuszczalna sól
KR102369405B1 (ko) * 2015-06-04 2022-03-02 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
WO2017021111A1 (en) * 2015-08-05 2017-02-09 Ratiopharm Gmbh New crystalline form and acetic acid adducts of palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN106474129A (zh) * 2015-09-01 2017-03-08 上海方楠生物科技有限公司 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
HU230962B1 (hu) * 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Compounds interacting with glycans and methods of use
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106800554A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二盐酸盐的晶型及其制备方法
CN106800553A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二羟乙基磺酸盐的晶型
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
CN107137408A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
CN107137409A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与***受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US10690673B2 (en) 2016-03-29 2020-06-23 Mayo Foundation For Medical Education And Research Method of treating cancer metastasis by CDK 4/6 inhibitors
WO2018001270A1 (en) * 2016-06-30 2018-01-04 Noratech Pharmaceuticals, Inc. Palbociclib prodrugs and composition thereof
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
MX2019000246A (es) 2016-07-07 2019-05-27 Plantex Ltd Formas en estado solido del dimesilato de palbociclib.
LT3497103T (lt) 2016-08-15 2021-07-26 Pfizer Inc. Piridopirimidinono cdk2/4/6 inhibitoriai
US10710999B2 (en) 2016-10-07 2020-07-14 Mylan Laboratories Limited Polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
EP3804724B1 (de) 2016-10-20 2022-12-07 Pfizer Inc. Cdk-inhibitoren zur behandlung von pah
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
EP3541847A4 (de) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
SI3546456T1 (sl) * 2016-11-28 2022-04-29 Teijin Pharma Limited Kristal derivata pirido(3,4-D)pirimidina ali njegovega solvata
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2018191950A1 (en) * 2017-04-21 2018-10-25 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
RU2019142591A (ru) 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
US11529353B2 (en) 2017-07-28 2022-12-20 Synthon B.V. Pharmaceutical composition comprising Palbociclib
BR112020015405A2 (pt) * 2018-01-29 2020-12-08 Beta Pharma, Inc. Compostos de 2h-indazóis como inibidores cdk4 e cdk6, composições farmacêuticas que os compreendem, seus usos terapêuticos e métodos de preparação
CA3092003A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
US11911383B2 (en) 2018-05-14 2024-02-27 Pfizer Inc. Oral solution formulation
AU2019310335A1 (en) 2018-07-23 2021-02-11 F. Hoffmann-La Roche Ag Methods of treating cancer with PI3K inhibitor, GDC-0077
KR20210049847A (ko) 2018-08-24 2021-05-06 쥐원 쎄라퓨틱스, 인크. 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
EP3863618A1 (de) 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Verfahren zur behandlung von krebs mit pi3k-alpha-inhibitoren und metformin
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
US20220125777A1 (en) 2019-02-01 2022-04-28 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
EP3976090A1 (de) 2019-05-24 2022-04-06 Pfizer Inc. Kombinationstherapien mit cdk-hemmern
EP3976043A1 (de) 2019-05-24 2022-04-06 Pfizer Inc. Kombinationstherapien mit cdk-hemmern
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
CA3156205A1 (en) 2019-12-03 2021-06-10 Jennifer O'hara Lauchle Combination therapies for treatment of breast cancer
WO2021176349A1 (en) 2020-03-05 2021-09-10 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
BR112023000687A2 (pt) 2020-07-15 2023-02-07 Pfizer Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CA3189632A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
WO2022063119A1 (zh) * 2020-09-24 2022-03-31 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
WO2023107525A1 (en) 2021-12-10 2023-06-15 Eli Lilly And Company Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302755A1 (de) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Eine aminosäure enthaltende palbociclib-formulierung
EP4302832A1 (de) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib-formulierung, die glucono-delta-lacton enthält
WO2024023703A1 (en) 2022-07-29 2024-02-01 Pfizer Inc. Dosing regimens comprising a kat6 inhibitor for the treatment of cancer
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720332B2 (en) * 2000-09-01 2004-04-13 Smithkline Beecham Corporation Oxindole derivatives
AU2002357164A1 (en) * 2001-12-17 2003-06-30 Smithkline Beecham Corporation Pyrazolopyridazine derivatives
ATE314370T1 (de) * 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
AU2003287178A1 (en) * 2002-10-10 2004-05-04 Smithkline Beecham Corporation Chemical compounds
KR20050085115A (ko) * 2002-11-22 2005-08-29 스미스클라인 비참 코포레이션 신규 화합물
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
JP2006519234A (ja) * 2003-02-27 2006-08-24 スミスクライン ビーチャム コーポレーション 新規化合物

Also Published As

Publication number Publication date
JP4053073B2 (ja) 2008-02-27
NL1026624C2 (nl) 2005-07-20
AR045898A1 (es) 2005-11-16
PA8606501A1 (es) 2005-03-03
PE20050700A1 (es) 2005-10-18
NO335100B1 (no) 2014-09-15
DK1648889T3 (da) 2009-01-05
IL173034A (en) 2010-06-16
KR100816945B1 (ko) 2008-03-25
US20050059670A1 (en) 2005-03-17
CN1835951B (zh) 2010-06-02
EP1648889B1 (de) 2008-10-29
TWI288750B (en) 2007-10-21
NO20060386L (no) 2006-04-05
TW200516079A (en) 2005-05-16
NL1026624A1 (nl) 2005-01-12
JP2007530425A (ja) 2007-11-01
AU2004255934B2 (en) 2010-02-25
WO2005005426A1 (en) 2005-01-20
PL1648889T3 (pl) 2009-03-31
GT200400130A (es) 2005-07-14
HK1091205A1 (en) 2007-01-12
US20080021037A1 (en) 2008-01-24
EP1648889A1 (de) 2006-04-26
KR20060054300A (ko) 2006-05-22
RU2317296C2 (ru) 2008-02-20
CL2004001701A1 (es) 2005-06-03
BRPI0412516A (pt) 2006-09-19
DE602004017474D1 (de) 2008-12-11
PT1648889E (pt) 2008-12-10
US7345171B2 (en) 2008-03-18
RU2006101052A (ru) 2006-07-27
MXPA06000484A (es) 2006-04-05
US7863278B2 (en) 2011-01-04
NZ544609A (en) 2008-07-31
CA2532049C (en) 2010-07-20
CY1108589T1 (el) 2014-04-09
CA2532049A1 (en) 2005-01-20
ZA200600230B (en) 2007-04-25
AU2004255934A1 (en) 2005-01-20
IL173034A0 (en) 2006-06-11
SI1648889T1 (sl) 2009-02-28
CN1835951A (zh) 2006-09-20
ES2313016T3 (es) 2009-03-01
UY28404A1 (es) 2005-02-28

Similar Documents

Publication Publication Date Title
ATE412650T1 (de) Isethionat salz eines selektiven cdk4 inhibitors
ATE373003T1 (de) Phosphorsäuresalz eines dipeptidylpeptidase-iv- inhibitors
FIC20240007I1 (fi) Gefapiksantti tai sen farmaseuttisesti hyväksyttävä suola
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
SE0701538L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
DK2439205T3 (da) Carboxamidforbindelser og deres anvendelse som calpaininhibitorer
CY2013042I2 (el) Αναστολεις πυριδυλιου της σηματοδοτησης hedgehog
ATE425152T1 (de) Aminocarbonylderivate als histone-deacetylase- inhibitoren
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
ATE395343T1 (de) Sulfonylderivate als histone-deacetylase- inhibitoren
ITVA20050027A1 (it) Metodo di generazione di successioni di numeri o bit pseudo casuali
DK1912949T3 (da) Cyclohexylaminisoquinolon-derivater som inhibitorer af rho-kinase
NO20044444L (no) Benzamidderivater nyttige som histondeacetylase inhibitorer
DE602006018355D1 (de) Transdermale verabreichung eines meptazinolsalzes
DE60320933D1 (de) Rho-kinase inhibitoren
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
NO20030867D0 (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
DE602004002028D1 (de) Integrität Merkmal eines Gewindes für ausdehnbare Rohrverbindungen
IS8201A (is) Nikótínamíð afleiður gagnlegar sem PDE4 hindrar
DK1501804T3 (da) Isoquinolinderivat MAO-B-inhibitorer
NO20044806L (no) N-acylaminobenzen-derivater som selektive monoamin-oksidase B inhibitorer
DE50311093D1 (de) Lagefixierung eines bolzens
DE602006008015D1 (de) Feste salzformen eines pyrrolsubstituierten 2-indolinons

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1648889

Country of ref document: EP